The drug ACRASON contains a combination of these active pharmaceutical ingredients (APIs):
Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the fungal cytoplasmic membrane. Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc.
This brand name is authorized in the following countries: Hong Kong
This drug has been assigned below unique identifiers within the countries it is being marketed: